Exploring the Bare Metal Stents Market: Trends, Growth Drivers, and Future Outlook

Introduction

In the ever-evolving field of cardiovascular healthcare, bare metal stents (BMS) have played a crucial role in treating coronary artery disease. Although drug-eluting stents (DES) have gained popularity in recent years, BMS still maintain a significant market presence, especially in regions with cost-sensitive healthcare systems or where long-term antiplatelet therapy isn’t viable. This article delves into the current state of the bare metal stents market, exploring key trends, market dynamics, technological advancements, and future prospects.

The global bare metal stents market size was valued at USD 9.08 billion in 2024 and is projected to reach USD 14.46 billion by 2032, with a CAGR of 5.98% during the forecast period of 2025 to 2032

To Know More Visit: https://www.databridgemarketresearch.com/reports/global-bare-metal-stents-market

What are Bare Metal Stents?

Bare metal stents are small mesh-like tubes made of metal, typically stainless steel or cobalt-chromium alloy, used to keep coronary arteries open after procedures like angioplasty. Unlike drug-eluting stents, they don’t have a polymer coating or medication to prevent restenosis (re-narrowing of the artery). BMS rely solely on mechanical scaffolding to restore blood flow.

Current Market Overview

The global bare metal stents market is projected to grow moderately due to the continued demand for affordable and reliable coronary intervention devices. In 2024, the market was valued at over USD 1 billion, and despite the growing preference for DES, BMS still have a firm foothold in specific segments.

Regions such as Latin America, the Middle East, and parts of Asia-Pacific rely on BMS because of their lower cost and accessibility. Additionally, BMS are favored in patients with high bleeding risks who cannot undergo prolonged dual antiplatelet therapy required for DES.

Key Market Drivers

Cost-effectiveness: One of the biggest advantages of BMS is their affordability compared to DES. This is especially crucial in emerging markets and public healthcare systems with limited budgets.
Shorter antiplatelet therapy duration: For patients who cannot tolerate long-term dual antiplatelet therapy due to bleeding disorders or upcoming surgeries, BMS are a better alternative.
Technological improvements: Newer generation bare metal stents with enhanced radial strength, flexibility, and improved biocompatibility are helping maintain their relevance in the market.
Rising prevalence of cardiovascular diseases: As heart diseases continue to be the leading cause of death globally, the demand for all types of stents, including BMS, remains strong.

Market Restraints

Despite their benefits, BMS face several limitations:

Higher restenosis rates: Compared to DES, BMS have a higher incidence of restenosis, which can necessitate repeat procedures.
Growing preference for DES: With falling costs of drug-eluting stents and improved outcomes, many cardiologists prefer DES over BMS.
Limited use in developed markets: In North America and Europe, BMS are increasingly being phased out in favor of more advanced stent technologies.

Regional Insights

North America: The market share for BMS is shrinking due to high adoption of advanced stents, though some niche applications persist.
Europe: Similar to North America, BMS usage is declining, but still exists in certain patient populations and budget-constrained hospital settings.
Asia-Pacific: Significant growth potential due to large patient pools, improving healthcare access, and government initiatives in countries like India and China.
Latin America & Middle East: These regions show steady demand driven by affordability, lower healthcare infrastructure costs, and fewer regulations compared to developed nations.

Technological Innovations in BMS

The stent industry is undergoing continuous innovation. While DES dominate the market, BMS are not stagnant. Key innovations include:

Thinner strut designs: Newer BMS have thinner struts which improve flexibility and lower the risk of restenosis.
Bioengineered coatings: Though not drug-eluting, some BMS now feature advanced coatings that promote faster healing and endothelialization.
Enhanced delivery systems: Modern BMS are equipped with better catheter systems for more precise placement and reduced procedural complications.

Competitive Landscape

Major players in the bare metal stents market include:

Medtronic
Boston Scientific
Abbott Laboratories
BIOTRONIK
Cook Medical
Terumo Corporation

These companies focus on maintaining a diversified portfolio that includes both BMS and DES to cater to a wider market segment.

Future Outlook

While the long-term future of BMS may see a gradual decline in developed regions, they will likely remain relevant in certain demographics and geographic areas. Strategic partnerships, regional expansions, and cost-effective manufacturing will be key for companies looking to retain market share.

Additionally, as global cardiovascular disease cases rise, the demand for all forms of stents, including BMS, is expected to continue, especially in healthcare systems where cost remains a limiting factor.

Conclusion

The bare metal stents market is undergoing a steady transformation. While drug-eluting stents dominate the conversation today, BMS still serve an essential role in modern cardiology. They are particularly valuable in cost-sensitive markets and specific clinical scenarios where DES are not ideal. By embracing innovation and adapting to shifting global needs, BMS will continue to be a relevant solution in the global cardiovascular care ecosystem.

FAQs

Why are bare metal stents still used today?
Bare metal stents are still used due to their lower cost and shorter required duration of antiplatelet therapy, especially for patients at high bleeding risk or in low-resource settings.
Are bare metal stents safe?
Yes, they are FDA-approved and considered safe for specific patient profiles. However, they may have a higher risk of restenosis compared to drug-eluting stents.
How long do bare metal stents last?
Once implanted, they are designed to be permanent. However, the long-term effectiveness can vary depending on patient health and lifestyle.
Which companies manufacture bare metal stents?
Major manufacturers include Medtronic, Abbott, Boston Scientific, and BIOTRONIK, among others.
Will bare metal stents be phased out?
While their use may decline in developed markets, they are unlikely to disappear entirely due to their affordability and continued need in specific clinical cases.